PriceTargets.com logo

Sorrento Therapeutics - SRNE Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.01 As of 04/26/2024 01:00 AM ET
▼ -0.01 (-42.19%)

This chart shows the closing price for SRNE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sorrento Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SRNE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SRNE

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Sorrento Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.01.

This chart shows the closing price for SRNE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Sorrento Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/13/2023Dawson JamesDowngradeBuy ➝ NeutralN/A
1/31/2023HC WainwrightLower Target$20.00 ➝ $13.00Low
11/2/2022Cantor FitzgeraldInitiated CoverageOverweight$5.00Low
3/25/2022HC WainwrightLower TargetBuy$26.00 ➝ $20.00Medium
11/15/2021HC WainwrightReiterated RatingBuy$25.00Medium
8/9/2021HC WainwrightLower TargetBuy$30.00 ➝ $26.00High
8/3/2021HC WainwrightReiterated RatingBuy$30.00Low
7/27/2021HC WainwrightReiterated RatingBuy$30.00Low
7/19/2021HC WainwrightReiterated RatingBuy$30.00Medium
7/7/2021HC WainwrightReiterated RatingBuy$30.00Medium
1/29/2021B. RileyInitiated CoverageBuy$26.00High
1/21/2021Alliance Global PartnersInitiated CoverageBuy$35.00Medium
7/31/2020HC WainwrightBoost TargetBuy$24.00 ➝ $30.00High
7/6/2020HC WainwrightReiterated RatingBuy$24.00High
6/11/2020HC WainwrightReiterated RatingBuy$24.00Medium
5/26/2020Dawson JamesInitiated CoverageBuy ➝ Buy$24.00Low
5/26/2020HC WainwrightReiterated RatingBuy$24.00Low
5/18/2020HC WainwrightReiterated RatingBuy$24.00High
3/30/2020HC WainwrightLower TargetBuy$28.00 ➝ $24.00High
10/7/2019JMP SecuritiesInitiated CoverageOutperform$21.00High
8/12/2019HC WainwrightReiterated RatingBuy$30.00Medium
7/23/2019HC WainwrightLower TargetBuy$40.00 ➝ $30.00High
(Data available from 4/26/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Sorrento Therapeutics logo
Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through the Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $0.01
Low: $0.01
High: $0.02

50 Day Range

MA: $0.02
Low: $0.01
High: $0.05

52 Week Range

Now: $0.01
Low: $0.00
High: $0.42

Volume

54,423 shs

Average Volume

482,392 shs

Market Capitalization

$7.55 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.25

Frequently Asked Questions

What sell-side analysts currently cover shares of Sorrento Therapeutics?

The following Wall Street analysts have issued stock ratings on Sorrento Therapeutics in the last year: StockNews.com.
View the latest analyst ratings for SRNE.

What is the current price target for Sorrento Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Sorrento Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Sorrento Therapeutics in the next year.
View the latest price targets for SRNE.

What is the current consensus analyst rating for Sorrento Therapeutics?

Sorrento Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SRNE.

What other companies compete with Sorrento Therapeutics?

Other companies that are similar to Sorrento Therapeutics include Genetic Technologies, Titan Pharmaceuticals, Creative Medical Technology, Organovo and BioCardia. Learn More about companies similar to Sorrento Therapeutics.

How do I contact Sorrento Therapeutics' investor relations team?

Sorrento Therapeutics' physical mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The biopharmaceutical company's listed phone number is (858) 203-4100 and its investor relations email address is [email protected]. The official website for Sorrento Therapeutics is www.sorrentotherapeutics.com. Learn More about contacing Sorrento Therapeutics investor relations.